Vincent Aurentz - Feb 21, 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Garth Lees-Rolfe, attorney-in-fact
Stock symbol
IKT
Transactions as of
Feb 21, 2025
Transactions value $
$0
Form type
4
Date filed
2/25/2025, 04:10 PM
Previous filing
Dec 2, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +134K $0.00 134K Feb 21, 2025 Common Stock 134K $2.23 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.